Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making?
作者信息
Suda Kenichi, Mitsudomi Tetsuya
机构信息
Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
出版信息
J Thorac Dis. 2020 May;12(5):1770-1775. doi: 10.21037/jtd-20-1661.
Abstract
摘要
相似文献
1
Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making?PD-L1状态的肿瘤间异质性：在临床决策中重要吗？
J Thorac Dis. 2020 May;12(5):1770-1775. doi: 10.21037/jtd-20-1661.
2
Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer.非小细胞肺癌中PD-L1表达的肿瘤间异质性。
J Thorac Dis. 2019 Dec;11(12):4982-4991. doi: 10.21037/jtd.2019.12.24.
3
Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response.非小细胞肺癌中 PD-L1 表达的异质性：对预测治疗反应的标本采样的影响。
Lung Cancer. 2019 Aug;134:79-84. doi: 10.1016/j.lungcan.2019.06.005. Epub 2019 Jun 5.
4
PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases.PD-L1 表达在肾透明细胞癌中的表达：肾切除术和转移部位的分析。
J Cancer. 2014 Jan 24;5(3):166-72. doi: 10.7150/jca.8167. eCollection 2014.
5
Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.肺癌配对原发灶与脑转移灶之间程序性细胞死亡配体1表达和淋巴细胞肿瘤浸润的时空不一致性。
Ann Oncol. 2016 Oct;27(10):1953-8. doi: 10.1093/annonc/mdw289. Epub 2016 Aug 8.
6
Comprehensive Assessment of PD-L1 Staining Heterogeneity in Pulmonary Adenocarcinomas Using Tissue Microarrays: Impact of the Architecture Pattern and the Number of Cores.使用组织微阵列对肺腺癌中 PD-L1 染色异质性进行全面评估：结构模式和核心数量的影响。
Am J Surg Pathol. 2018 May;42(5):687-694. doi: 10.1097/PAS.0000000000001013.
7
Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.多中心分析性比较研究使用四种临床开发的免疫组织化学检测方法，检测尿路上皮膀胱癌肿瘤浸润免疫细胞和肿瘤细胞程序性死亡配体 1 的表达。
Virchows Arch. 2019 Nov;475(5):599-608. doi: 10.1007/s00428-019-02610-z. Epub 2019 Jul 2.
8
Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma.四种临床开发的程序性死亡配体1免疫组织化学检测方法在晚期透明细胞肾细胞癌中的多中心分析及观察者间可比性
Clin Genitourin Cancer. 2020 Oct;18(5):e629-e642. doi: 10.1016/j.clgc.2020.02.009. Epub 2020 Feb 15.
9
PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies.新辅助治疗环境下的 PD-L1 检测：三阴性乳腺癌中 PD-L1 表达的肿瘤内异质性对小活检评估的影响。
Breast Cancer Res Treat. 2020 Jun;181(3):553-560. doi: 10.1007/s10549-020-05655-w. Epub 2020 May 2.
10
Concordance of PD-L1 Expression Between Core Biopsy and Resection Specimens of Non-Small Cell Lung Cancer.非小细胞肺癌核心穿刺活检与切除标本中 PD-L1 表达的一致性。
Am J Surg Pathol. 2018 Aug;42(8):1090-1094. doi: 10.1097/PAS.0000000000001085.
引用本文的文献
1
Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma.对ORACLE（一种与肺腺癌患者生存相关的克隆表达生物标志物）进行前瞻性验证。
Nat Cancer. 2025 Jan;6(1):86-101. doi: 10.1038/s43018-024-00883-1. Epub 2025 Jan 9.
2
Preclinical antibody-PET imaging of PD-L1.程序性死亡配体 1（PD-L1）的临床前抗体正电子发射断层扫描（PET）成像
Front Nucl Med. 2022 Aug 9;2:953202. doi: 10.3389/fnume.2022.953202. eCollection 2022.
3
Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities.探索PD-1/PD-L1成像示踪剂领域：从挑战到机遇
Front Med (Lausanne). 2024 Jun 7;11:1401515. doi: 10.3389/fmed.2024.1401515. eCollection 2024.
4
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours.定义实体瘤中免疫检查点抑制剂的临床有用生物标志物。
Nat Rev Cancer. 2024 Jul;24(7):498-512. doi: 10.1038/s41568-024-00705-7. Epub 2024 Jun 12.
5
quantification of programmed death-ligand-1 expression heterogeneity in tumors using fluorescence lifetime imaging.使用荧光寿命成像技术对肿瘤中程序性死亡配体-1表达异质性进行定量分析。
Res Sq. 2023 Oct 23:rs.3.rs-3222037. doi: 10.21203/rs.3.rs-3222037/v1.
6
PD-L1, a Master Regulator of Immunity 2.0.PD-L1，免疫调控大师 2.0。
Int J Mol Sci. 2023 Feb 23;24(5):4385. doi: 10.3390/ijms24054385.
7
Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors.肺癌免疫疗法：超越常见免疫检查点抑制剂
Cancers (Basel). 2022 Dec 13;14(24):6145. doi: 10.3390/cancers14246145.
8
Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌中免疫检查点抑制剂的当前和未来生物标志物。
Curr Oncol. 2022 Jun 8;29(6):4185-4198. doi: 10.3390/curroncol29060334.
9
The current state of molecular profiling in gastrointestinal malignancies.胃肠恶性肿瘤中分子谱分析的现状。
Biol Direct. 2022 Jun 6;17(1):15. doi: 10.1186/s13062-022-00322-0.
10
Immunotherapy in Lung Cancer: Current Landscape and Future Directions.肺癌的免疫治疗：现状与未来方向。
Front Immunol. 2022 Feb 9;13:823618. doi: 10.3389/fimmu.2022.823618. eCollection 2022.
本文引用的文献
1
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.肺腺癌患者 PD-L1 表达的临床和分子相关性。
Ann Oncol. 2020 May;31(5):599-608. doi: 10.1016/j.annonc.2020.01.065. Epub 2020 Feb 6.
2
Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer.非小细胞肺癌中PD-L1表达的肿瘤间异质性。
J Thorac Dis. 2019 Dec;11(12):4982-4991. doi: 10.21037/jtd.2019.12.24.
3
Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer.非小细胞肺癌中原发性肿瘤与淋巴结转移灶之间PD-L1表达的一致性评估
Onco Targets Ther. 2019 Dec 30;12:11541-11547. doi: 10.2147/OTT.S223643. eCollection 2019.
4
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.高 PD-L1 表达的晚期非小细胞肺癌中转移性部位与一线帕博利珠单抗治疗结局的相关性：一项回顾性多中心队列研究。
Invest New Drugs. 2020 Feb;38(1):211-218. doi: 10.1007/s10637-019-00882-5. Epub 2019 Nov 30.
5
Mechanisms regulating PD-L1 expression on tumor and immune cells.调控肿瘤细胞和免疫细胞 PD-L1 表达的机制。
J Immunother Cancer. 2019 Nov 15;7(1):305. doi: 10.1186/s40425-019-0770-2.
6
A clonal expression biomarker associates with lung cancer mortality.一种克隆表达生物标志物与肺癌死亡率相关。
Nat Med. 2019 Oct;25(10):1540-1548. doi: 10.1038/s41591-019-0595-z. Epub 2019 Oct 7.
7
Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response.非小细胞肺癌中 PD-L1 表达的异质性：对预测治疗反应的标本采样的影响。
Lung Cancer. 2019 Aug;134:79-84. doi: 10.1016/j.lungcan.2019.06.005. Epub 2019 Jun 5.
8
Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer.恶性胸腔积液作为抗 PD-1 抗体治疗非小细胞肺癌患者疗效的预测指标。
Thorac Cancer. 2019 Apr;10(4):815-822. doi: 10.1111/1759-7714.13004. Epub 2019 Feb 14.
9
PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes.非小细胞肺癌包括各种腺癌亚型中的程序性死亡受体配体1（PD-L1）表达
Ann Thorac Cardiovasc Surg. 2019 Feb 20;25(1):1-9. doi: 10.5761/atcs.oa.18-00163. Epub 2018 Oct 3.
10
Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC).非小细胞肺癌（NSCLC）患者对nivolumab 的器官特异性反应。
Cancer Immunol Immunother. 2018 Dec;67(12):1825-1832. doi: 10.1007/s00262-018-2239-4. Epub 2018 Aug 31.
Zotero 插件